StockWatch
·

LINCOLN PHARMACEUTICALS LTD. Q4 FY25 Results

LINCOLNQ4 FY25 Results
Filing
MetricValue ( Cr)vs Q3 FY25
Revenue168.1814.8%
Total Income161.303.7%
Expenditure145.0614.4%
PBT16.2543.4%
Net Profit11.5744.3%
OPM15.89%5.14pp
NPM7.18%6.17pp
EPS5.7844.3%
View full financials

Informational and educational content only. Not investment advice.